Progress on the maintenance therapy of advanced non-small cell lung cancer / 肿瘤研究与临床

ABSTRACT

Presently platinum-based doublets chemotherapy is the first-line treatment for advanced non-small-cell lung cancer patient .However, the efficacy of standard first-line treatment has stagnated.Maintenance therapy for patients with advanced NSCLC who responded to initial therapy has become a focus.Summarization:first, Pem maintenance therapy is well tolerated and offers superior OS and PFS, making it a new treatment paradigm for patients with advanced NSCLC who responded to initial therapy, especially Pem has greater efficacy in patients with non-squamous. Secondly, first-line chemotherapy followed Erlotinib prolongs survival in patient with advanced NSCLC. It has proved that Erlotinib as maintenance therapy is an active and well tolerated treatment after standard therapy in nearly all the patients with advanced NSCLC.No matter what pathological type, race, sex, age and cigarette smoking or not, Gefitinib maintenance therapy offers superior OS and PFS for patients with adenocarcinoma, who has accepted platinum-based doublets chemotherapy.